Core Insights - Dangbei is offering significant discounts on its 4K home cinema and portable projectors during a limited-time promotion on Amazon.com, with savings of up to 47.4% and as much as $900 off selected models [3][12]. Product Offerings - The Dangbei DBOX02, a flagship 4K ALPD laser projector, is now priced at $999, down from $1,899, providing a 47.4% discount [6][7]. - The DBOX02 Pro, featuring a flexible gimbal stand, is available for $899, a 43.8% reduction from its original price of $1,599 [8]. - The MP1 Max, a 4K Hybrid Tri-Laser + LED projector, is now $1,399, reflecting a 30.0% discount from $1,999 [9]. - The Dangbei Atom, an ultra-slim laser projector, is priced at $549, down 38.9% from $899 [10]. - The portable Freedo projector is available for $349, a 36.4% discount from $549 [11]. - The compact N2 mini projector is now $149, down from $229, offering a 34.9% discount [12]. Promotional Period - The promotional offers are exclusively available on the Dangbei Store on Amazon.com from December 2 to December 15, 2025, targeting consumers looking for affordable home entertainment solutions during the holiday season [12]. Company Overview - Dangbei is recognized as a premium provider of smart entertainment solutions, specializing in home and portable projectors, with over 200 million users globally [13].

DECLARATION DU NOMBRE D’ACTIONS COMPOSANT LE CAPITALET DU NOMBRE TOTAL DE DROITS DE VOTE AU 30 NOVEMBRE 2025 Article L. 233-8-II du Code de CommerceArticle 223-16 du Règlement général de l’AMF Nombre d’actions composant le capital social237 553 695Nombre de droits de vote théoriques287 011 643Nombre de droits de vote exerçables282 190 807 Cette déclaration est en ligne sur le site internet d’Elis www.elis.com DISCLOSURE OF THE NUMBER OF SHARES FORMING THE CAPITALAND OF THE TOTAL NUMBER OF VOTING RIGHTS AS O ...

Arizona Rodeo Committee awarded new Massey Ferguson tractor Massey Ferguson Names Prescott Frontier Days 2025 Sowing Good Deeds Winner Representatives from Massey Ferguson and the Prescott Frontier Days Rodeo celebrate the 2025 Sowing Good Deeds winner announcement in Las Vegas. In a release issued under the same headline on Dec. 4, 2025 by AGCO Corporation, please note that the quote in paragraph 5 was attributed to the wrong person. The corrected release follows: LAS VEGAS, Dec. 05, 2025 (GLOBE NEWSWI ...

Core Viewpoint - Junshi Biosciences announced the acceptance of the new drug application (NDA) for roconkibart injection, a treatment for moderate to severe plaque psoriasis, by the National Medical Products Administration (NMPA) in China [1][5]. Company Overview - Junshi Biosciences is an innovation-driven biopharmaceutical company founded in December 2012, focusing on the discovery, development, and commercialization of innovative therapeutics [8]. - The company has a diversified R&D pipeline with over 50 drug candidates across five therapeutic areas: cancer, autoimmune, metabolic, neurological, and infectious diseases [8]. - Junshi has achieved significant milestones, including the approval of five products in China and international markets, notably toripalimab, which is China's first domestically produced anti-PD-1 monoclonal antibody [8]. Product Details - Roconkibart (JS005) is a recombinant humanized anti-IL-17A monoclonal antibody designed to treat moderate to severe plaque psoriasis by targeting the inflammatory pathway associated with the disease [1][6]. - The NDA submission is based on a pivotal phase 3 clinical study involving 747 patients across 60 clinical sites in China, demonstrating significant efficacy and a favorable safety profile [3][4]. Clinical Study Insights - The phase 3 clinical study showed that treatment with roconkibart for 12 weeks resulted in significant improvements in the Psoriasis Area and Severity Index (PASI) scores and static Physician Global Assessment (sPGA) scores compared to the placebo group [4]. - The efficacy of roconkibart was maintained throughout a 52-week treatment period, indicating its potential as a long-term treatment option for patients [4]. Market Implications - The acceptance of the NDA is seen as a critical step in transitioning roconkibart from clinical research to real-world application, with expectations for early approval to enhance treatment options for patients in China [5]. - The company aims to collaborate closely with regulatory authorities to expedite the product's market approval process [5].

Nexus 7 Elements LLC formed to deploy CHIPS™ technology across ACRG’s nationwide critical minerals operationsRENO, Nev., Dec. 05, 2025 (GLOBE NEWSWIRE) -- American Clean Resources Group Inc. (OTC: ACRG), a critical minerals processing company, announced the formation of Nexus 7 Elements LLC, a joint venture with Energ4 Mining Company LLC to commercialize rare earth element and mineral recovery technology across ACRG’s processing hub network. “By combining our feedstock access and infrastructure with Energ4' ...

Core Points - Embassy Bancorp, Inc. has promoted Jeffrey Skumin to Chief Financial Officer (CFO) effective December 31, 2025, to guide the financial strategy and growth of the company and its subsidiary, Embassy Bank for the Lehigh Valley [1] - Mr. Skumin has been with Embassy since March 2020, serving as Executive Vice President of Finance, and has played a significant role in the company's financial management [2] - Prior to joining Embassy, Mr. Skumin had a 19-year career as a CPA, including serving as an audit partner and Chief Accounting Officer for a large regional bank, enhancing his banking industry experience [3][4] Company Overview - Embassy Bancorp, Inc. is a community bank with $1.7 billion in assets, operating since 2001 with 10 branches and a full suite of digital banking services [4] - As of June 2025, Embassy Bank ranks 4th in deposit market share in Lehigh and Northampton Counties and has received multiple accolades, including "Best Bank" from The Morning Call and Lehigh Valley Style, and a 5-star rating from Bauer Financial for strength and stability [5]

Core Insights - Sunrise New Energy Co., Ltd. has been granted a patent for a method to enhance the fast-charging performance of silicon-carbon composite anode materials, indicating a significant technological advancement in the field [1][2][3] Company Developments - The patented technology addresses critical challenges in silicon-carbon composite anode materials, such as interfacial instability and insufficient ion transport efficiency, thereby improving electrochemical performance under high-rate charging conditions [2][3] - The company plans to increase investment in advanced anode material research and accelerate the pilot-scale validation and industrialization of its innovative technologies, reinforcing its leadership in solid-state battery materials and fast-charging anode materials [4] Industry Context - Silicon-carbon materials are recognized as a key focus for the development of future solid-state battery anodes, and the patent strengthens the company's position in this critical area [3] - The advancements in this technology are expected to enhance the competitiveness of the company in fast-charging batteries, energy storage systems, and solid-state battery supply chains [3]

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE IN THIS STOCK EXCHANGE RELEASE BELOW. Series 1 tranche 2 offering of UAB „Atsinaujinan ...

Core Insights - Algorhythm Holdings, Inc. has announced a joint sales and marketing agreement between SemiCab and Provisi.ai to enhance the launch of SemiCab's new Apex SaaS platform targeting U.S.-based 3PLs and enterprise shippers [1][3] Company Overview - Algorhythm Holdings, Inc. is a leading AI technology company focused on the growth of SemiCab, which addresses supply-chain problems globally through its AI-enabled, cloud-based Collaborative Transportation Platform [7] - SemiCab's technology aims to optimize logistics by using real-time data and advanced predictive optimization models to enable fully loaded round trips [7] Partnership Details - Provisi.ai, led by Shane Engle, has a strong track record in executing complex SaaS product launches within the Fortune 500 market, including significant contracts worth up to $100 million annually [2][3] - The partnership is expected to leverage Provisi.ai's access to Fortune 500 clients to promote SemiCab's value proposition, particularly in reducing empty miles and increasing profitability [3][5] Market Potential - The U.S. full-truckload (FTL) total addressable market is approximately $450 billion, presenting a significant opportunity for SemiCab's Apex platform [3] - It is estimated that around $150 billion, or 30-35%, of U.S. annual shipping spend is wasted on empty miles, which SemiCab aims to reduce by 70% through its technology [5] Apex Platform Features - SemiCab Apex extends the company's AI-driven orchestration engine to the U.S. market, enabling enterprise-level supply chains to predict, plan, and profit with precision [4] - The platform allows 3PLs and enterprise shippers to create branded logistics operating systems, integrate with existing systems, and leverage predictive analytics for cost savings and efficiency improvements [6]

Core Viewpoint - EUDA Health Holdings Limited has entered into a securities purchase agreement with Streeterville Capital for a convertible warrant, aiming to strengthen its capital position and support growth strategies in the non-invasive healthcare market in Asia [1][4]. Company Overview - EUDA Health Holdings Limited is a Singapore-based non-invasive healthcare provider focusing on Singapore, Malaysia, and China, with a mission to lead the transformation of healthcare from reactive treatment to proactive, longevity-focused care [5]. - The company targets the fast-growing longevity sector, addressing the healthcare needs of over 1.8 billion people in the region, where more than 30% of the population is aging rapidly [5]. Financial Details - The securities purchase agreement involves the sale of a convertible warrant for an aggregate purchase price of US$100,000, which is exercisable for up to 2,000,000 newly issued ordinary shares at an exercise price of US$6.00 per share [1][3]. - The warrant can be exercised for cash within a 90-day period, with conditions allowing the company to require Streeterville Capital to exercise the warrant under specific trading volume and price conditions [3]. Strategic Intent - The CEO of EUDA emphasized that the warrant financing provides flexibility to invest in high-return initiatives, including new centers, partnerships, and technology, to expand the company's footprint in Asia's non-invasive healthcare market [4].